A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
209627(DREAMM 13)
Phase 1 other active
Quick answer
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function for Relapsed or Refractory Multiple Myeloma is a Phase 1 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- other
- Status
- active